Maturamap - AI assisted therapeutic antibody design

Purpose and goal

The Maturamab project involves developing bioinformatic tools that, combined with AAX Biotech’s proprietary interaction mapping method Seqitope, enable the rapid design of therapeutic antibodies with enhanced properties, such as increased affinity, higher production levels, and improved stability. This advancement would empower AAX Biotech to contribute sustainable and effective therapeutic solutions to critical health challenges, including cancer, autoimmune diseases, and pandemic preparedness.

Expected effects and result

With the Maturamab tools, AAX Biotech AB will make a valuable contribution to the therapeutic antibody field. These tools provide a deep understanding of how specific mutations at various amino acid positions influence key antibody properties, such as affinity, stability, and expression levels. This insight will accelerate the development of the next generation therapeutic antibodies, saving both time and valuable resources, and contributing to global health and environmental sustainability.

Planned approach and implementation

The Maturamab tools will leverage the extensive datasets generated by AAX Biotech’s proprietary Seqitope interaction mapping method. These datasets, rich in untapped information, provide an excellent foundation for training machine learning algorithms, as confirmed in a pilot study with an external partner. As the project progresses, additional Seqitope datasets will be generated to validate the Maturamab tools.